Cancer Genetics Inc (CGIX)

Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

Cancer Genetics to Present at the Annual 33rd ROTH Conference

Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

Looking For Biotech Stocks To Buy Now? 4 Names To Know

As the biotech companies continue to unveil new drugs and therapies, these biotech stocks are in focus.

Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today

CGIX stock is on the move Wednesday ahead of a shareholder vote on its merger with StemoniX. Here's what you should know now.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates NK, ALXN, CATM, CGIX, MTSC; Shareholders Are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm NEW YORK, NY / ACCESSWIRE / February 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: PRGX Global, Inc. (NASDAQ: PRGX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ardian

Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market

Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOS